Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer. - Shiyuan Wang; Qi Zhang; Chunlu Yu; Yiyin Cao; Yongchun Zuo; Lei Yang (Briefings Bioinform., 2021)

Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer. - Shiyuan Wang; Yuqiang Xiong; Qi Zhang; Dongqing Su; Chunlu Yu; Yiyin Cao; Yi Pan; Qianzi Lu; Yongchun Zuo; Lei Yang (Briefings Bioinform., 2021)

A differentiable path-following method to compute subgame perfect equilibria in stationary strategies in robust stochastic games and its applications. - Yiyin Cao; Chuangyin Dang; Zhongdong Xiao (Eur. J. Oper. Res., 2022)

A variant of Harsanyi's tracing procedures to select a perfect equilibrium in normal form games. - Yiyin Cao; Chuangyin Dang (Games Econ. Behav., 2022)

Complementarity Enhanced Nash's Mappings and Differentiable Homotopy Methods to Select Perfect Equilibria. - Yiyin Cao; Chuangyin Dang; Yabin Sun (J. Optim. Theory Appl., 2022)

A Differentiable Path-Following Method with a Compact Formulation to Compute Proper Equilibria. - Yiyin Cao; Yin Chen; Chuangyin Dang (INFORMS J. Comput., 2024)

A Variant of the Logistic Quantal Response Equilibrium to Select a Perfect Equilibrium. - Yiyin Cao; Yin Chen; Chuangyin Dang (J. Optim. Theory Appl., 2024)

How the agency contract fails in hybrid mode: agency fees and distribution sequences. - Wenjun Shu; Zhongdong Xiao; Yiyin Cao (Int. Trans. Oper. Res., 2024)

Variants of Harsanyi's tracing procedures for selecting a perfect stationary equilibrium in stochastic games. - Yiyin Cao; Peixuan Li; Chuangyin Dang (Comput. Oper. Res., 2025)

A Sequence-Form Characterization and Differentiable Path-Following Computation of Normal-Form Perfect Equilibria in Extensive-Form Games. - Yuqing Hou; Yiyin Cao; Chuangyin Dang (CoRR, 2025)

A sequence-form differentiable path-following method to compute Nash equilibria. - Yuqing Hou; Yiyin Cao; Chuangyin Dang; Yong Wang (Comput. Optim. Appl., 2025)